JP7034093B2 - 胆汁酸誘導体、特に、オベチコール酸の合成のための中間体 - Google Patents
胆汁酸誘導体、特に、オベチコール酸の合成のための中間体 Download PDFInfo
- Publication number
- JP7034093B2 JP7034093B2 JP2018560597A JP2018560597A JP7034093B2 JP 7034093 B2 JP7034093 B2 JP 7034093B2 JP 2018560597 A JP2018560597 A JP 2018560597A JP 2018560597 A JP2018560597 A JP 2018560597A JP 7034093 B2 JP7034093 B2 JP 7034093B2
- Authority
- JP
- Japan
- Prior art keywords
- general formula
- compound
- ethyl
- alkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[C@](**)[C@@](C(*)CC1C2[C@@]3O[C@@]33)[C@@]1(C)C(*)CC2[C@@](C)(CC1)C3=CC1=O Chemical compound C[C@](**)[C@@](C(*)CC1C2[C@@]3O[C@@]33)[C@@]1(C)C(*)CC2[C@@](C)(CC1)C3=CC1=O 0.000 description 27
- BLULDOYKONEKNT-VZGPSVMVSA-N CC[C@H]([C@H](C(C(CC1)[C@](C)(CC2)[C@H]1[C@H](C)C1OCCO1)C2[C@@]1(C)CC2)O)C1=CC2=O Chemical compound CC[C@H]([C@H](C(C(CC1)[C@](C)(CC2)[C@H]1[C@H](C)C1OCCO1)C2[C@@]1(C)CC2)O)C1=CC2=O BLULDOYKONEKNT-VZGPSVMVSA-N 0.000 description 2
- AEHDDUVMOHSQLA-RTMNDGLTSA-N CC[C@H]([C@H](CC(CC1)=O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)CO)C2=O Chemical compound CC[C@H]([C@H](CC(CC1)=O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)CO)C2=O AEHDDUVMOHSQLA-RTMNDGLTSA-N 0.000 description 2
- VJQNUMWDGXIULT-XPDLBSRASA-N CC(C(CC1)CC1[C@H](C)/C=C/C(O)=O)/C=C\C(C)=C Chemical compound CC(C(CC1)CC1[C@H](C)/C=C/C(O)=O)/C=C\C(C)=C VJQNUMWDGXIULT-XPDLBSRASA-N 0.000 description 1
- VKMSDGFCLFPMBZ-SNOQJCIASA-N CC([C@@H](CC1)[C@@](C)(CC2)C1C(CC1)C2[C@@](C)(CC2)C1=CC2=O)/C=C/C(OC)=O Chemical compound CC([C@@H](CC1)[C@@](C)(CC2)C1C(CC1)C2[C@@](C)(CC2)C1=CC2=O)/C=C/C(OC)=O VKMSDGFCLFPMBZ-SNOQJCIASA-N 0.000 description 1
- ITYSIMQOOKKRIQ-DFUXRKGMSA-N CCCC[C@H](CCC[C@@H](CC(CCCC1)C2C(CC3)[C@@H]1[C@H]3[C@H](C)CCC(OCC)=O)[C@@H](CC)[C@H]2O)O Chemical compound CCCC[C@H](CCC[C@@H](CC(CCCC1)C2C(CC3)[C@@H]1[C@H]3[C@H](C)CCC(OCC)=O)[C@@H](CC)[C@H]2O)O ITYSIMQOOKKRIQ-DFUXRKGMSA-N 0.000 description 1
- ISYYVDHLLGOZDL-HLPAKBADSA-N CCOC1=CC2=CCC(C(CC3)[C@](C)(CC4)/C3=C\C)C4[C@@]2(C)CC1 Chemical compound CCOC1=CC2=CCC(C(CC3)[C@](C)(CC4)/C3=C\C)C4[C@@]2(C)CC1 ISYYVDHLLGOZDL-HLPAKBADSA-N 0.000 description 1
- PAOWPNQOTVTCAF-CEJNIXRPSA-N CCOC1=CC2=CCC(C(CC3)[C@](C)(CC4)C3=O)C4[C@@]2(C)CC1 Chemical compound CCOC1=CC2=CCC(C(CC3)[C@](C)(CC4)C3=O)C4[C@@]2(C)CC1 PAOWPNQOTVTCAF-CEJNIXRPSA-N 0.000 description 1
- RBKVSSUSNVWTQR-GEIKIYMTSA-N CC[C@@H](C(CC(CC1)=O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)C1OCCO1)C2=O Chemical compound CC[C@@H](C(CC(CC1)=O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)C1OCCO1)C2=O RBKVSSUSNVWTQR-GEIKIYMTSA-N 0.000 description 1
- QJTBGQZGNFYMNL-UTJJRMSRSA-N CC[C@@H]([C@H](CC(CC1)=O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)C1OCCO1)[C@H]2O Chemical compound CC[C@@H]([C@H](CC(CC1)=O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)C1OCCO1)[C@H]2O QJTBGQZGNFYMNL-UTJJRMSRSA-N 0.000 description 1
- SDWKKDYWQLIHTJ-MOKPAOHHSA-N CC[C@@H]([C@H](CC(CC1)=O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)COC(C)=O)C2=O Chemical compound CC[C@@H]([C@H](CC(CC1)=O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)COC(C)=O)C2=O SDWKKDYWQLIHTJ-MOKPAOHHSA-N 0.000 description 1
- KLLCFALDLRPUAL-YAZQTBQQSA-N CC[C@@H]([C@H](C[C@@H](CC1)O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)C3[C@H](C)CCC#N)C2=O Chemical compound CC[C@@H]([C@H](C[C@@H](CC1)O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)C3[C@H](C)CCC#N)C2=O KLLCFALDLRPUAL-YAZQTBQQSA-N 0.000 description 1
- WTYLFIWEKIPVOE-VTXFIDRTSA-N CC[C@H](C(C[C@@H](CC1)O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)C1OCCO1)[C@H]2O Chemical compound CC[C@H](C(C[C@@H](CC1)O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)C1OCCO1)[C@H]2O WTYLFIWEKIPVOE-VTXFIDRTSA-N 0.000 description 1
- WCQAEILCSRENTJ-IHCIKXCISA-N CC[C@H](C(C[C@@H](CC1)O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)C=O)[C@H]2O Chemical compound CC[C@H](C(C[C@@H](CC1)O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)C=O)[C@H]2O WCQAEILCSRENTJ-IHCIKXCISA-N 0.000 description 1
- XYDZIJHBYDZJBX-HOCLPQALSA-N CC[C@H]([C@H](C(C(CC1)[C@](C)(CC2)[C@H]1[C@H](C)COC(C)=O)C2[C@@]1(C)CC2)O)C1=CC2=O Chemical compound CC[C@H]([C@H](C(C(CC1)[C@](C)(CC2)[C@H]1[C@H](C)COC(C)=O)C2[C@@]1(C)CC2)O)C1=CC2=O XYDZIJHBYDZJBX-HOCLPQALSA-N 0.000 description 1
- GVCWHPRVYZASSR-UMLBLZRNSA-N CC[C@H]([C@H](C[C@@H](CC1)O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)C3[C@H](C)CC(C(OC)=O)C(OC)=O)[C@H]2O Chemical compound CC[C@H]([C@H](C[C@@H](CC1)O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)C3[C@H](C)CC(C(OC)=O)C(OC)=O)[C@H]2O GVCWHPRVYZASSR-UMLBLZRNSA-N 0.000 description 1
- NXWBUJTVUODBDH-AOMZEDORSA-N CC[C@H]([C@H](C[C@@H](CC1)O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)CO)C2=O Chemical compound CC[C@H]([C@H](C[C@@H](CC1)O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)CO)C2=O NXWBUJTVUODBDH-AOMZEDORSA-N 0.000 description 1
- HFMKHYOWVKMNEP-YAKGRZQSSA-N C[C@@H](C(CC1)[C@@](C)(CC2)C1C(C(C)C1)C2[C@@](C)(CC2)C1=CC2=O)/C=C/C(NS(c(cc1)ccc1OC(F)(F)F)(=O)=O)=O Chemical compound C[C@@H](C(CC1)[C@@](C)(CC2)C1C(C(C)C1)C2[C@@](C)(CC2)C1=CC2=O)/C=C/C(NS(c(cc1)ccc1OC(F)(F)F)(=O)=O)=O HFMKHYOWVKMNEP-YAKGRZQSSA-N 0.000 description 1
- HEWUXAJMGXSQGO-PJNNBAIBSA-N C[C@@H]([C@@H](CC1)[C@@](C)(CC2)C1C([C@@H]1O[C@@H]11)C2[C@@](C)(CC2)C1=CC2=O)C1OCCO1 Chemical compound C[C@@H]([C@@H](CC1)[C@@](C)(CC2)C1C([C@@H]1O[C@@H]11)C2[C@@](C)(CC2)C1=CC2=O)C1OCCO1 HEWUXAJMGXSQGO-PJNNBAIBSA-N 0.000 description 1
- YVCBLKBIDFHGRX-ODXXYEORSA-N C[C@@H]([C@@H](CC1)[C@@](C)(CCC2[C@@](C)(CCC(C3)=O)C3/C3=C/C)C1C2[C@@H]3O)C1OCCO1 Chemical compound C[C@@H]([C@@H](CC1)[C@@](C)(CCC2[C@@](C)(CCC(C3)=O)C3/C3=C/C)C1C2[C@@H]3O)C1OCCO1 YVCBLKBIDFHGRX-ODXXYEORSA-N 0.000 description 1
- KHTUVUCNCJLOEA-ULSNSLLASA-N C[C@H](C1OCCO1)[C@@H](CC1)[C@H](C)C(CCC2[C@@]3(C)CC4)C1C2C=CC3=CC4=O Chemical compound C[C@H](C1OCCO1)[C@@H](CC1)[C@H](C)C(CCC2[C@@]3(C)CC4)C1C2C=CC3=CC4=O KHTUVUCNCJLOEA-ULSNSLLASA-N 0.000 description 1
- BPJILYQVEOOXOT-RUVWXEBDSA-N C[C@H](CBr)C(CC1)C(C)(CC2)C1C1C2C(C)(CCC2(C3)OCCO2)C3=CC1 Chemical compound C[C@H](CBr)C(CC1)C(C)(CC2)C1C1C2C(C)(CCC2(C3)OCCO2)C3=CC1 BPJILYQVEOOXOT-RUVWXEBDSA-N 0.000 description 1
- DVGPACHJMSFAIS-TYKADPJKSA-N C[C@H](CBr)C(CC1)C(C)(CCC2[C@@]3(C)CC4)C1C2C=CC3=CC4=O Chemical compound C[C@H](CBr)C(CC1)C(C)(CCC2[C@@]3(C)CC4)C1C2C=CC3=CC4=O DVGPACHJMSFAIS-TYKADPJKSA-N 0.000 description 1
- IVQCOMWNAITTKW-VCGIBUFOSA-N C[C@H](CBr)C(CC1)[C@@](C)(CC2)C1C(CC1)C2[C@@](C)(CC2)C1=CC21OCCO1 Chemical compound C[C@H](CBr)C(CC1)[C@@](C)(CC2)C1C(CC1)C2[C@@](C)(CC2)C1=CC21OCCO1 IVQCOMWNAITTKW-VCGIBUFOSA-N 0.000 description 1
- YLUICUWPZQNMPS-KGLOXSIVSA-N C[C@H](CBr)C(CC1)[C@@](C)(CC2)C1C(CC1CC3C4)C2[C@@](C)(CC2)[C@@]13[C@@H]4C21OCCO1 Chemical compound C[C@H](CBr)C(CC1)[C@@](C)(CC2)C1C(CC1CC3C4)C2[C@@](C)(CC2)[C@@]13[C@@H]4C21OCCO1 YLUICUWPZQNMPS-KGLOXSIVSA-N 0.000 description 1
- HZMGKPMNRMHRMD-KBEWHFDLSA-N C[C@H](CC#N)C(CC1)[C@@](C)(CC2)C1C(CC1)C2[C@@](C)(CC2)C1=CC2=O Chemical compound C[C@H](CC#N)C(CC1)[C@@](C)(CC2)C1C(CC1)C2[C@@](C)(CC2)C1=CC2=O HZMGKPMNRMHRMD-KBEWHFDLSA-N 0.000 description 1
- QDVBJYWNHOKQTC-JBLPTAOASA-N C[C@H](CC#N)C(CC1)[C@@](C)(CC2)C1C([C@@H]1O[C@@H]11)C2[C@@](C)(CC2)C1=CC2=O Chemical compound C[C@H](CC#N)C(CC1)[C@@](C)(CC2)C1C([C@@H]1O[C@@H]11)C2[C@@](C)(CC2)C1=CC2=O QDVBJYWNHOKQTC-JBLPTAOASA-N 0.000 description 1
- BNJBNUKQHKMQRE-FVUFJZHCSA-N C[C@H](CC#N)[C@@H](CC1)[C@@](C)(CCC2[C@@]3(C)CC4)C1C2C=CC3=CC4=O Chemical compound C[C@H](CC#N)[C@@H](CC1)[C@@](C)(CCC2[C@@]3(C)CC4)C1C2C=CC3=CC4=O BNJBNUKQHKMQRE-FVUFJZHCSA-N 0.000 description 1
- IYCJJFKNIVDSEC-RIHLLPQHSA-N C[C@H](CCC#N)C(CC1)[C@@](C)(CC2)C1C(CC1CC3C4)C2[C@@](C)(CC2)[C@@]13C4C21OCCO1 Chemical compound C[C@H](CCC#N)C(CC1)[C@@](C)(CC2)C1C(CC1CC3C4)C2[C@@](C)(CC2)[C@@]13C4C21OCCO1 IYCJJFKNIVDSEC-RIHLLPQHSA-N 0.000 description 1
- ZQQPNEANPAYUGN-VHPLENGMSA-N C[C@H](CN)C(CC1)[C@@](C)(CCC2[C@@]3(C)CC4)C1C2C=CC3=CC4=O Chemical compound C[C@H](CN)C(CC1)[C@@](C)(CCC2[C@@]3(C)CC4)C1C2C=CC3=CC4=O ZQQPNEANPAYUGN-VHPLENGMSA-N 0.000 description 1
- ZQQPNEANPAYUGN-IESYDMTLSA-N C[C@H](CN)[C@@H](CC1)[C@@](C)(CCC2[C@@]3(C)CC4)C1C2C=CC3=CC4=O Chemical compound C[C@H](CN)[C@@H](CC1)[C@@](C)(CCC2[C@@]3(C)CC4)C1C2C=CC3=CC4=O ZQQPNEANPAYUGN-IESYDMTLSA-N 0.000 description 1
- ZNWOYQVXPIEQRC-VHPLENGMSA-N C[C@H](CO)C(CC1)[C@@](C)(CC2)C1C(CC1)C2[C@@](C)(CC2)C1=CC2=O Chemical compound C[C@H](CO)C(CC1)[C@@](C)(CC2)C1C(CC1)C2[C@@](C)(CC2)C1=CC2=O ZNWOYQVXPIEQRC-VHPLENGMSA-N 0.000 description 1
- DHGPNOCJHVBWQT-ANZJRBOASA-N C[C@H](CO)C(CC1)[C@@](C)(CCC2C3)C1C2C=CC3=C Chemical compound C[C@H](CO)C(CC1)[C@@](C)(CCC2C3)C1C2C=CC3=C DHGPNOCJHVBWQT-ANZJRBOASA-N 0.000 description 1
- WJKJZKIHLUIQTO-VHPLENGMSA-N C[C@H](CO)C(CC1)[C@@](C)(CCC2[C@@]3(C)CC4)C1C2C=CC3=CC4=O Chemical compound C[C@H](CO)C(CC1)[C@@](C)(CCC2[C@@]3(C)CC4)C1C2C=CC3=CC4=O WJKJZKIHLUIQTO-VHPLENGMSA-N 0.000 description 1
- NTXWUXDNKRIRJL-ZQWRRFPKSA-N C[C@H](COC(C)=O)C(CC1)[C@@](C)(CCC2[C@@]3(C)CC4)C1C2C=CC3=CC4=O Chemical compound C[C@H](COC(C)=O)C(CC1)[C@@](C)(CCC2[C@@]3(C)CC4)C1C2C=CC3=CC4=O NTXWUXDNKRIRJL-ZQWRRFPKSA-N 0.000 description 1
- NCVOUGLRYJUZCS-VFSAMASDSA-N C[C@H](COC(C)=O)[C@@H](CC1)[C@@](C)(CC2)C1C([C@@H]1O[C@@H]11)C2[C@@](C)(CC2)C1=CC2=O Chemical compound C[C@H](COC(C)=O)[C@@H](CC1)[C@@](C)(CC2)C1C([C@@H]1O[C@@H]11)C2[C@@](C)(CC2)C1=CC2=O NCVOUGLRYJUZCS-VFSAMASDSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/006—Ketals at position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/008—Ketals at position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1608777.7A GB201608777D0 (en) | 2016-05-18 | 2016-05-18 | Compounds |
| GB1608777.7 | 2016-05-18 | ||
| PCT/GB2017/051385 WO2017199033A1 (en) | 2016-05-18 | 2017-05-18 | Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516720A JP2019516720A (ja) | 2019-06-20 |
| JP2019516720A5 JP2019516720A5 (https=) | 2020-07-02 |
| JP7034093B2 true JP7034093B2 (ja) | 2022-03-11 |
Family
ID=56320629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560597A Active JP7034093B2 (ja) | 2016-05-18 | 2017-05-18 | 胆汁酸誘導体、特に、オベチコール酸の合成のための中間体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10968250B2 (https=) |
| EP (2) | EP3458469B1 (https=) |
| JP (1) | JP7034093B2 (https=) |
| KR (1) | KR102458265B1 (https=) |
| CN (1) | CN109415407B (https=) |
| AU (1) | AU2017266539B2 (https=) |
| EA (1) | EA037584B1 (https=) |
| ES (2) | ES2970336T3 (https=) |
| GB (1) | GB201608777D0 (https=) |
| HR (1) | HRP20211128T1 (https=) |
| HU (1) | HUE054851T2 (https=) |
| MX (1) | MX378591B (https=) |
| PT (1) | PT3458469T (https=) |
| WO (1) | WO2017199033A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201608776D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
| EP3431486A1 (en) * | 2017-07-18 | 2019-01-23 | Bionice, S.L.U. | Process and intermediates for the synthesis of obeticholic acid and derivatives thereof |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| CN111138509B (zh) * | 2018-11-02 | 2022-12-06 | 东莞东阳光药物研发有限公司 | 奥贝胆酸的制备方法 |
| CN111072744B (zh) * | 2019-12-03 | 2021-09-14 | 江苏佳尔科药业集团股份有限公司 | 一种以ba为原料合成熊去氧胆酸的方法 |
| CN114315945A (zh) * | 2020-09-28 | 2022-04-12 | 四川澄华生物科技有限公司 | 一种胆甾酸及其衍生物的除杂方法 |
| CN112341516B (zh) * | 2020-11-14 | 2022-07-15 | 湖南科瑞生物制药股份有限公司 | 5,6-环氧类固醇类化合物及其制备方法和应用 |
| EP4423105A2 (en) * | 2021-11-02 | 2024-09-04 | Sandhill One, LLC | High purity non-animal derived udca |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007080951A1 (ja) | 2006-01-12 | 2007-07-19 | Mitsubishi Chemical Corporation | ステロイド化合物の製造方法 |
| WO2016079519A1 (en) | 2014-11-19 | 2016-05-26 | Dextra Laboratories Limited | 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators |
| WO2016079520A1 (en) | 2014-11-19 | 2016-05-26 | Dextra Laboratories Limited | 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators |
| WO2016079518A1 (en) | 2014-11-19 | 2016-05-26 | Dextra Laboratories Limited | 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators |
| WO2016079517A1 (en) | 2014-11-19 | 2016-05-26 | Dextra Laboratories Limited | 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2624748A (en) | 1950-09-09 | 1953-01-06 | Upjohn Co | Bisnorchola-4, 6-dien-3-one-22-al |
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| CA2118130A1 (en) | 1992-04-14 | 1993-10-28 | Jean M. J. Frechet | Dendritic based macromolecules and method of production |
| WO1994019366A1 (en) | 1993-02-26 | 1994-09-01 | Magainin Pharmaceuticals Inc. | Chemical synthesis of squalamine |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| ES2248581T3 (es) | 2001-03-12 | 2006-03-16 | Intercept Pharmaceuticals, Inc. | Esteroides como agonistas de fxr. |
| US20090062256A1 (en) | 2001-06-01 | 2009-03-05 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
| AU2002352524B2 (en) | 2001-11-07 | 2007-10-04 | Nektar Therapeutics | Branched polymers and their conjugates |
| EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| CN101374854A (zh) * | 2006-01-12 | 2009-02-25 | 三菱化学株式会社 | 甾类化合物的制备方法 |
| CN101395170A (zh) | 2006-02-14 | 2009-03-25 | 英特塞普特药品公司 | 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物 |
| US7932244B2 (en) | 2006-06-27 | 2011-04-26 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions |
| KR101555716B1 (ko) | 2007-01-19 | 2015-09-25 | 인터셉트 파마슈티컬즈, 인크. | Ｔｇｒ5 조절제로서의 23-치환 담즙산 및 이의 사용 방법 |
| WO2010014836A2 (en) | 2008-07-30 | 2010-02-04 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
| DK2698375T3 (en) | 2008-11-19 | 2018-05-28 | Intercept Pharmaceuticals Inc | TGR5 modulators and methods for using them |
| ES2774368T3 (es) | 2008-11-19 | 2020-07-20 | Intercept Pharmaceuticals Inc | Moduladores de TGR5 y métodos de uso de los mismos |
| EP2459581A4 (en) | 2009-07-29 | 2012-12-26 | Univ Chicago | LIVER X-RECEPTOR AGONISTS |
| SI3336097T1 (sl) | 2012-06-19 | 2021-07-30 | Intercept Pharmaceuticals, Inc. | Priprava nekristalinične oblike obetiholne kisline |
| SG11201503247UA (en) | 2012-10-26 | 2015-06-29 | Intercept Pharmaceuticals Inc | Process for preparing bile acid derivatives |
| AU2013352288B2 (en) | 2012-11-28 | 2017-11-23 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
| US20140206657A1 (en) * | 2013-01-18 | 2014-07-24 | City Of Hope | Bile acid analog tgr5 agonists |
| TN2015000497A1 (en) | 2013-05-14 | 2017-04-06 | Intercept Pharmaceuticals Inc | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
| SG11201509371XA (en) | 2013-05-24 | 2015-12-30 | Nestec Sa | Pathway specific markers for diagnosing irritable bowel syndrome |
| US10166246B2 (en) | 2014-05-27 | 2019-01-01 | City Of Hope | TGR5 agonist complexes for treating diabetes and cancer |
| SMT202000070T1 (it) | 2014-05-29 | 2020-03-13 | Bar Pharmaceuticals S R L | Derivati del colano per l'uso del trattamento e/o la prevenzione di malattie mediate da fxr e tgr5/gpbar1 |
| SG11201703717SA (en) | 2014-11-06 | 2017-06-29 | Enanta Pharm Inc | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
| EP3223823A4 (en) | 2014-11-26 | 2018-10-17 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| US11578097B2 (en) | 2014-11-26 | 2023-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| WO2016086134A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| CN105348365A (zh) * | 2014-12-03 | 2016-02-24 | 四川百利药业有限责任公司 | 一种胆酸衍生物及其制备方法、药物组合物和用途 |
| CN106279328A (zh) | 2015-05-20 | 2017-01-04 | 重庆药友制药有限责任公司 | 一种制备6α-烷基鹅去氧胆酸的方法 |
| JP6861703B2 (ja) | 2015-06-19 | 2021-04-21 | インターセプト ファーマシューティカルズ， インコーポレイテッド | Ｔｇｒ５修飾物質およびその使用方法 |
| CN106397522A (zh) | 2015-07-31 | 2017-02-15 | 中国人民解放军军事医学科学院毒物药物研究所 | 3,7‑二（叔丁基二甲基硅基氧基）‑6‑烯‑5β‑胆烷‑24‑酸甲酯 |
| CN106478759A (zh) | 2015-08-31 | 2017-03-08 | 陕西合成药业股份有限公司 | 奥贝胆酸衍生物及其制备方法和用途 |
| CN106478756A (zh) | 2015-09-02 | 2017-03-08 | 中美华世通生物医药科技（武汉）有限公司 | Oca-e单晶及其制备方法和用途 |
| CN106518946A (zh) | 2015-09-10 | 2017-03-22 | 上海迪诺医药科技有限公司 | 磺酰脲衍生物、其药物组合物及应用 |
| GB201608776D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
| GB201608779D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
-
2016
- 2016-05-18 GB GBGB1608777.7A patent/GB201608777D0/en not_active Ceased
-
2017
- 2017-05-18 EP EP17725740.9A patent/EP3458469B1/en active Active
- 2017-05-18 HR HRP20211128TT patent/HRP20211128T1/hr unknown
- 2017-05-18 ES ES21160246T patent/ES2970336T3/es active Active
- 2017-05-18 WO PCT/GB2017/051385 patent/WO2017199033A1/en not_active Ceased
- 2017-05-18 MX MX2018014164A patent/MX378591B/es unknown
- 2017-05-18 PT PT177257409T patent/PT3458469T/pt unknown
- 2017-05-18 JP JP2018560597A patent/JP7034093B2/ja active Active
- 2017-05-18 ES ES17725740T patent/ES2878577T3/es active Active
- 2017-05-18 HU HUE17725740A patent/HUE054851T2/hu unknown
- 2017-05-18 AU AU2017266539A patent/AU2017266539B2/en active Active
- 2017-05-18 EA EA201892514A patent/EA037584B1/ru unknown
- 2017-05-18 CN CN201780030532.1A patent/CN109415407B/zh active Active
- 2017-05-18 KR KR1020187035834A patent/KR102458265B1/ko active Active
- 2017-05-18 EP EP21160246.1A patent/EP3848382B1/en active Active
- 2017-05-18 US US16/302,059 patent/US10968250B2/en active Active
-
2021
- 2021-02-26 US US17/186,272 patent/US11479577B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007080951A1 (ja) | 2006-01-12 | 2007-07-19 | Mitsubishi Chemical Corporation | ステロイド化合物の製造方法 |
| WO2016079519A1 (en) | 2014-11-19 | 2016-05-26 | Dextra Laboratories Limited | 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators |
| WO2016079520A1 (en) | 2014-11-19 | 2016-05-26 | Dextra Laboratories Limited | 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators |
| WO2016079518A1 (en) | 2014-11-19 | 2016-05-26 | Dextra Laboratories Limited | 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators |
| WO2016079517A1 (en) | 2014-11-19 | 2016-05-26 | Dextra Laboratories Limited | 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators |
Non-Patent Citations (3)
| Title |
|---|
| Biosci. Biotechnol. Biochem.，68，2004年，1332-1337 |
| Chemistry and Physics of Lipids，2001年，109，135-143 |
| J. Org. Chem.，2002年，67，6764-6771 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX378591B (es) | 2025-03-11 |
| PT3458469T (pt) | 2021-06-11 |
| US10968250B2 (en) | 2021-04-06 |
| EP3848382B1 (en) | 2023-11-29 |
| MX2018014164A (es) | 2019-04-01 |
| JP2019516720A (ja) | 2019-06-20 |
| HUE054851T2 (hu) | 2021-10-28 |
| US20210179661A1 (en) | 2021-06-17 |
| US20190284227A1 (en) | 2019-09-19 |
| ES2970336T3 (es) | 2024-05-28 |
| AU2017266539A1 (en) | 2018-11-15 |
| EA201892514A1 (ru) | 2019-05-31 |
| CN109415407B (zh) | 2021-08-17 |
| CA3024281A1 (en) | 2017-11-23 |
| HRP20211128T1 (hr) | 2022-01-07 |
| EP3458469B1 (en) | 2021-04-14 |
| GB201608777D0 (en) | 2016-06-29 |
| EP3848382A1 (en) | 2021-07-14 |
| AU2017266539B2 (en) | 2021-04-15 |
| EP3458469A1 (en) | 2019-03-27 |
| US11479577B2 (en) | 2022-10-25 |
| ES2878577T3 (es) | 2021-11-19 |
| CN109415407A (zh) | 2019-03-01 |
| EP3848382C0 (en) | 2023-11-29 |
| BR112018073488A2 (pt) | 2019-04-09 |
| KR102458265B1 (ko) | 2022-10-25 |
| EA037584B1 (ru) | 2021-04-16 |
| WO2017199033A1 (en) | 2017-11-23 |
| KR20190009322A (ko) | 2019-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7034093B2 (ja) | 胆汁酸誘導体、特に、オベチコール酸の合成のための中間体 | |
| JP7034092B2 (ja) | 化学的中間体としてのステロイド６．７．β－エポキシド | |
| CN107207559B (zh) | 作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇 | |
| CN107108688B (zh) | 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇 | |
| JP7034094B2 (ja) | ステロイド４，６－ジエンの６，７－α－エポキシ化のための方法及び中間体 | |
| CN107108687B (zh) | 作为制备类固醇FXR调节剂的中间体的5β-6-烷基-7-羟基-3-酮类固醇 | |
| CN107207558B (zh) | 作为制备类固醇FXR调节剂的中间体的6α-烷基-6,7-二酮类固醇 | |
| HK1244287B (en) | 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200515 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200515 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210608 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210902 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211118 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220208 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220301 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7034093 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |